KD 101
Alternative Names: KD101Latest Information Update: 28 Jul 2018
At a glance
- Originator Kwang Dong Pharmaceutical
- Class Obesity therapies; Sesquiterpenes; Small molecules; Terpenes
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for phase-I development in Obesity in South Korea (PO)
- 28 Jun 2016 Seoul National University Hospital plans a phase I trial in Healthy volunteers in South Korea (PO) (NCT02819934)
- 01 Mar 2015 Phase-I clinical trials in Obesity in South Korea (PO)